<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828321</url>
  </required_header>
  <id_info>
    <org_study_id>40179</org_study_id>
    <nct_id>NCT00828321</nct_id>
  </id_info>
  <brief_title>Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions</brief_title>
  <official_title>Randomized , 2- Way Crossover, Bioequivalence Study of Ramipril 10 mg Capsule and Altace® Administered as 1 x 10 mg Capsule in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of ramipril 10 mg&#xD;
      capsule (test) versus Altace® (reference), administered as 1 x 10 mg capsule under fasting&#xD;
      conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description&#xD;
&#xD;
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
&#xD;
      Outcome: Confidence interval fell within 80-125% therefore met the FDA Bioequivalence&#xD;
      criteria; no drug related, serious, unexpected adverse events were reported during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum Observed Concentration of Drug Substance in Plasma)of Ramipril</measure>
    <time_frame>Blood samples collected over a 72 hour period.</time_frame>
    <description>Bioequivalence based on Cmax of Ramipril.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)of Ramipril</measure>
    <time_frame>Blood samples collected over a 72 hour period.</time_frame>
    <description>Bioequivalence based on AUC0-t of Ramipril.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)of Ramipril.</measure>
    <time_frame>Blood samples collected over a 72 hour period.</time_frame>
    <description>Bioequivalence based on AUC0-t for Ramipril.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (Maximum Observed Concentration of Drug Substance in Plasma)of Ramiprilat.</measure>
    <time_frame>Blood samples collected over a 72 hour period.</time_frame>
    <description>Informational comparison of Cmax values for the metabolite Ramiprilat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-72 (Area Under the Concentration-time Curve From Time Zero to Time 72 Hours)of Ramiprilat.</measure>
    <time_frame>Blood samples collected over a 72 hour period.</time_frame>
    <description>Informational comparison of AUC0-72 values for the metabolite Ramiprilat.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril 10 mg capsule</intervention_name>
    <description>1 x 10 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Altace® 10 mg capsule</intervention_name>
    <description>1 x 10 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-childbearing potential female, light smoker of non-smoker 18 years of age&#xD;
             and older.&#xD;
&#xD;
          -  Capable of consent&#xD;
&#xD;
          -  Non-childbearing potential female subject is defined as follows:&#xD;
&#xD;
          -  Post-menopausal state: absence of menses for 12 months prior to drug administration or&#xD;
             hysterectomy with bilateral oophorectomy at least 6 months prior to drug&#xD;
             administration, or&#xD;
&#xD;
          -  Surgically sterile: hysterectomy, bilateral oophorectomy, or tubule ligation at least&#xD;
             6 months prior to drud administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks prior to the administration of the&#xD;
             study medication.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the Medical Sub- Investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant, specifically BUN, serum&#xD;
             creatinine and hyperkalemia.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.&#xD;
&#xD;
          -  EcG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 100 or over 140 mmHg, diastolic blood pressure lower than 60 or&#xD;
             over 90 mmHg, or heart rate less than 50 or over 100 bpm) or change in the systolic&#xD;
             blood pressure of 20 mmHg, or diastolic blood pressure of 10mmHg when passing from&#xD;
             supine (after at least 5 minutes) to standing position ( after 1-3 minutes), at&#xD;
             screening.&#xD;
&#xD;
          -  BMI ≥30.0kg/m2.&#xD;
&#xD;
          -  History of significant alcohol abuse within 6 months prior to the screening visit of&#xD;
             any indication of the regular use of more than 14 units of alcohol per week ( 1 Unit=&#xD;
             150 mL of wine, 360 mL of beer, or 45 mL of 40% hard alcohol), or positive alcohol&#xD;
             breath test at screening.&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)&#xD;
             within 3 months prior to the screening visit of hard drugs (such as cocaine,&#xD;
             phencyclidine [PCP] and crack) within 1 year prior to the screening visit of positive&#xD;
             urine drug screen at screening.&#xD;
&#xD;
          -  History of allergic reactions to heparin, ramipril, or other ACE inhibitors, or other&#xD;
             related drugs.&#xD;
&#xD;
          -  Use of any drugs known to induce hepatic drug metabolism (examples of inducers:&#xD;
             barbiturates, carbamazepine, phenytoine, glucocorticoids, omeprazole; examples of&#xD;
             inhibitors: antidepressant (SSRI), cimetidine, diltiazem, macrolides, imidazoles,&#xD;
             neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to&#xD;
             administration of the study medication.&#xD;
&#xD;
          -  Use of and investigational drug or participation in an investigational study within 30&#xD;
             days prior to administration of the study medication.&#xD;
&#xD;
          -  Clinically significant history or presence of any clinically significant&#xD;
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),&#xD;
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver of kidney&#xD;
             disease, or other conditions known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of hte drug.&#xD;
&#xD;
          -  Any clinically significant history or presence of clinically significant neurological,&#xD;
             endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or&#xD;
             metabolic disease.&#xD;
&#xD;
          -  Use of prescription medication ( including hormone replacement therapy) within 14 days&#xD;
             prior to administration of study medication or over-the-counter products (including&#xD;
             natural food supplements, vitamins, garlic as a supplement) within 7 days prior to&#xD;
             administration of study medication, except for topical products without systemic&#xD;
             absorption.&#xD;
&#xD;
          -  Difficulty to swallow study medication.&#xD;
&#xD;
          -  Smoking more than 10 cigarettes per day.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             Medical Sub-Investigator, could contraindicate the subject's participation in this&#xD;
             study.&#xD;
&#xD;
          -  A depot injection or an implant of any drug within 3 months prior to administration of&#xD;
             study medication.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 30 days prior to drug administration. Donation or&#xD;
             loss of whole blood (excluding the volume of blood that will be drawn during the&#xD;
             screening procedures of this study) prior to administration of the study medication as&#xD;
             follows:&#xD;
&#xD;
          -  50 mL to 300 mL of whole blood within 30 days,&#xD;
&#xD;
          -  301 mL to 500 mL of whole blood within 45 days, or&#xD;
&#xD;
          -  more than 500 mL of whole blood within 56 days prior to drug administration.&#xD;
&#xD;
          -  Intolerance to venipunctures&#xD;
&#xD;
          -  Clinically significant history of renal, hepatic or cardiovascular disease,&#xD;
             tuberculosis, epilepsy, asthma, diabetes, psychosis or glaucoma will nor be eligible&#xD;
             for this study.&#xD;
&#xD;
          -  Unable to understand or unwilling to sign the Informed Consent Form.&#xD;
&#xD;
          -  Clinically significant history of angioedema.&#xD;
&#xD;
          -  History of known presence of volume-depletion (diuretics, dialysis, gastrointestinal&#xD;
             disease) or hypotension.&#xD;
&#xD;
          -  History of collagen-vascular disease and/or renal disease.&#xD;
&#xD;
          -  History of ischemic heart disease, congestive heart failure, or cerebrovascular&#xD;
             disease.&#xD;
&#xD;
          -  Breast-feeding subject.&#xD;
&#xD;
          -  Positive urine pregnancy test at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Larouche, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>January 12, 2009</study_first_submitted>
  <study_first_submitted_qc>January 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2009</study_first_posted>
  <results_first_submitted>July 2, 2009</results_first_submitted>
  <results_first_submitted_qc>July 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2009</results_first_posted>
  <last_update_submitted>September 1, 2009</last_update_submitted>
  <last_update_submitted_qc>September 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2009</last_update_posted>
  <keyword>Bioequivalency</keyword>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test (Ramipril) First</title>
          <description>10 mg Ramipril Capsules test product dosed in first period followed by 10 mg Altace® Capsules reference product dosed in the second period.</description>
        </group>
        <group group_id="P2">
          <title>Reference (Altace®) First</title>
          <description>10 mg Altace® Capsules reference product dosed in first period followed by 10 mg Ramipril Capsules test product dosed in the second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout of 42 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test (Ramipril) First</title>
          <description>10 mg Ramipril Capsules test product dosed in first period followed by 10 mg Altace® Capsules reference product dosed in the second period.</description>
        </group>
        <group group_id="B2">
          <title>Reference (Altace®) First</title>
          <description>10 mg Altace® Capsules reference product dosed in first period followed by 10 mg Ramipril Capsules test product dosed in the second period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma)of Ramipril</title>
        <description>Bioequivalence based on Cmax of Ramipril.</description>
        <time_frame>Blood samples collected over a 72 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Ramipril)</title>
            <description>10 mg Ramipril Capsules test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Altace®)</title>
            <description>10 mg Altace® Capsules reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma)of Ramipril</title>
          <description>Bioequivalence based on Cmax of Ramipril.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24243.26" spread="10801.83"/>
                    <measurement group_id="O2" value="25646.69" spread="10793.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>94.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>85.08</ci_lower_limit>
            <ci_upper_limit>104.21</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)of Ramipril</title>
        <description>Bioequivalence based on AUC0-t of Ramipril.</description>
        <time_frame>Blood samples collected over a 72 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Ramipril)</title>
            <description>10 mg Ramipril Capsules test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Altace®)</title>
            <description>10 mg Altace® Capsules reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)of Ramipril</title>
          <description>Bioequivalence based on AUC0-t of Ramipril.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20716.92" spread="8241.81"/>
                    <measurement group_id="O2" value="20859.98" spread="9796.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>102.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>96.21</ci_lower_limit>
            <ci_upper_limit>108.6</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)of Ramipril.</title>
        <description>Bioequivalence based on AUC0-t for Ramipril.</description>
        <time_frame>Blood samples collected over a 72 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Ramipril)</title>
            <description>10 mg Ramipril Capsules test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Altace®)</title>
            <description>10 mg Altace® Capsules reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)of Ramipril.</title>
          <description>Bioequivalence based on AUC0-t for Ramipril.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21310.07" spread="8422.26"/>
                    <measurement group_id="O2" value="21406.11" spread="9997.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>102.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>96.34</ci_lower_limit>
            <ci_upper_limit>108.58</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma)of Ramiprilat.</title>
        <description>Informational comparison of Cmax values for the metabolite Ramiprilat.</description>
        <time_frame>Blood samples collected over a 72 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Ramipril)</title>
            <description>10 mg Ramipril Capsules test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Altace®)</title>
            <description>10 mg Altace® Capsules reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma)of Ramiprilat.</title>
          <description>Informational comparison of Cmax values for the metabolite Ramiprilat.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25892.38" spread="17462.37"/>
                    <measurement group_id="O2" value="26154.13" spread="18380.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>98.52</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.63</ci_lower_limit>
            <ci_upper_limit>104.79</ci_upper_limit>
            <estimate_desc>This analysis was for informational purposes and was not used to establish bioequivalence.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-72 (Area Under the Concentration-time Curve From Time Zero to Time 72 Hours)of Ramiprilat.</title>
        <description>Informational comparison of AUC0-72 values for the metabolite Ramiprilat.</description>
        <time_frame>Blood samples collected over a 72 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Test (Ramipril)</title>
            <description>10 mg Ramipril Capsules test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Reference (Altace®)</title>
            <description>10 mg Altace® Capsules reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-72 (Area Under the Concentration-time Curve From Time Zero to Time 72 Hours)of Ramiprilat.</title>
          <description>Informational comparison of AUC0-72 values for the metabolite Ramiprilat.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196669.75" spread="69676.68"/>
                    <measurement group_id="O2" value="201747.51" spread="73592.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>97.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>94.66</ci_lower_limit>
            <ci_upper_limit>100.32</ci_upper_limit>
            <estimate_desc>This analysis was for informational purposes only and was not used to establish bioequivalence.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>TEVA Pharmaceuticals, USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

